|
1
|
Chi L, Zhou W, Prikhozhan A, et al:
Cloning and characterization of the human GnRH receptor. Mol Cell
Endocrinol. 91:R1–R6. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lariviere S, Garrel G, Simon V, et al:
Gonadotropin-releasing hormone couples to 3′,5′-cyclic
adenosine-5′-monophosphate pathway through novel protein kinase
Cdelta and -epsilon in LbetaT2 gonadotrope cells. Endocrinology.
148:1099–1107. 2007.
|
|
3
|
Limonta P, Moretti RM, Marelli MM and
Motta M: The biology of gonadotropin hormone-releasing hormone:
role in the control of tumor growth and progression in humans.
Front Neuroendocrinol. 24:279–295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee E, Schumacher F, Lewinger JP, et al:
The association of polymorphisms in hormone metabolism pathway
genes, menopausal hormone therapy, and breast cancer risk: a nested
case-control study in the California Teachers Study cohort. Breast
Cancer Res. 13:R372011. View
Article : Google Scholar
|
|
5
|
Udler MS, Azzato EM, Healey CS, et al:
Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1
and STS and survival after a diagnosis of breast cancer. Int J
Cancer. 125:2687–2696. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L, Gu L, Qian B, et al: Association
of genetic polymorphisms of ER-alpha and the estradiol-synthesizing
enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese
women. Breast Cancer Res Treat. 114:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diergaarde B, Potter JD, Jupe ER, et al:
Polymorphisms in genes involved in sex hormone metabolism, estrogen
plus progestin hormone therapy use, and risk of postmenopausal
breast cancer. Cancer Epidemiol Biomarkers Prev. 17:1751–1759.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ralph DA, Zhao LP, Aston CE, et al:
Age-specific association of steroid hormone pathway gene
polymorphisms with breast cancer risk. Cancer. 109:1940–1948. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Emons G, Ortmann O, Becker M, et al: High
affinity binding and direct antiproliferative effects of LHRH
analogues in human ovarian cancer cell lines. Cancer Res.
53:5439–5446. 1993.PubMed/NCBI
|
|
10
|
Emons G, Schroder B, Ortmann O, Westphalen
S, Schulz KD and Schally AV: High affinity binding and direct
antiproliferative effects of luteinizing hormone-releasing hormone
analogs in human endometrial cancer cell lines. J Clin Endocrinol
Metab. 77:1458–1464. 1993.
|
|
11
|
Cheung LW, Leung PC and Wong AS:
Gonadotropin-releasing hormone promotes ovarian cancer cell
invasiveness through c-Jun NH2-terminal kinase-mediated activation
of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res.
66:10902–10910. 2006. View Article : Google Scholar
|
|
12
|
Fost C, Duwe F, Hellriegel M, Schweyer S,
Emons G and Grundker C: Targeted chemotherapy for triple-negative
breast cancers via LHRH receptor. Oncol Rep. 25:1481–1487.
2011.PubMed/NCBI
|
|
13
|
Schubert A, Hawighorst T, Emons G and
Gründker C: Agonists and antagonists of GnRH-I and -II reduce
metastasis formation by triple-negative human breast cancer cells
in vivo. Breast Cancer Res Treat. 130:783–790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torrisi R, Bagnardi V, Rotmensz N, et al:
Letrozole plus GnRH analogue as preoperative and adjuvant therapy
in premenopausal women with ER positive locally advanced breast
cancer. Breast Cancer Res Treat. 126:431–441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grundker C, Fost C, Fister S, Nolte N,
Gunthert AR and Emons G: Gonadotropin-releasing hormone type II
antagonist induces apoptosis in MCF-7 and triple-negative
MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast
Cancer Res. 12:R492010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emons G, Kaufmann M, Gorchev G, et al:
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an
LHRH agonist linked to doxorubicin, in women with LHRH
receptor-positive tumors. Gynecol Oncol. 119:457–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye S, Dhillon S, Ke X, Collins AR and Day
IN: An efficient procedure for genotyping single nucleotide
polymorphisms. Nucleic Acids Res. 29:E88. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harlid S, Ivarsson MI, Butt S, et al:
Combined effect of low-penetrant SNPs on breast cancer risk. Br J
Cancer. 106:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pelletier C, Speed WC, Paranjape T, et al:
Rare BRCA1 haplotypes including 3′UTR SNPs associated with breast
cancer risk. Cell Cycle. 10:90–99. 2011.
|
|
20
|
Han W, Kang SY, Kang D, et al: Multiplex
genotyping of 1107 SNPs from 232 candidate genes identified an
association between IL1A polymorphism and breast cancer risk. Oncol
Rep. 23:763–769. 2010.PubMed/NCBI
|
|
21
|
Hamacher R, Diersch S, Scheibel M, et al:
Interleukin 1 beta gene promoter SNPs are associated with risk of
pancreatic cancer. Cytokine. 46:182–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park IH, Lee YS, Lee KS, et al: Single
nucleotide polymorphisms of CYP19A1 predict clinical outcomes and
adverse events associated with letrozole in patients with
metastatic breast cancer. Cancer Chemother Pharmacol. 68:1263–1271.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Q, Yang G, Wang Y, et al: Common
genetic variation in the 3′-untranslated region of
gonadotropin-releasing hormone receptor regulates gene expression
in cells and is associated with thyroid function, insulin secretion
as well as insulin sensitivity in polycystic ovary syndrome
patients. Hum Genet. 129:553–561. 2011.
|
|
24
|
Vagenakis GA, Sgourou A, Papachatzopoulou
A, Kourounis G, Papavassiliou AG and Georgopoulos NA: The
gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor
gene, and their promoters in patients with idiopathic
hypogonadotropic hypogonadism with or without resistance to GnRH
action. Fertil Steril. 84:1762–1765. 2005. View Article : Google Scholar
|
|
25
|
Lanfranco F, Gromoll J, von Eckardstein S,
Herding EM, Nieschlag E and Simoni M: Role of sequence variations
of the GnRH receptor and G protein-coupled receptor 54 gene in male
idiopathic hypogonadotropic hypogonadism. Eur J Endocrinol.
153:845–852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valkenburg O, Uitterlinden AG, Piersma D,
et al: Genetic polymorphisms of GnRH and gonadotrophic hormone
receptors affect the phenotype of polycystic ovary syndrome. Hum
Reprod. 24:2014–2022. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Piersma D, Themmen AP, Look MP, et al:
GnRH and LHR gene variants predict adverse outcome in premenopausal
breast cancer patients. Breast Cancer Res. 9:R512007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nanao K and Hasegawa Y: Polymorphisms at
the 5′ end of the human gonadotropin-releasing hormone receptor
gene are not associated with the timing of menarche in Japanese
girls. Eur J Endocrinol. 143:555–556. 2000.
|
